Medical Ventures Corp.

Medical Ventures Corp.

September 05, 2007 09:00 ET

Medical Ventures Corp.: U.S. Cardiovascular Conference to Include Metricath Libra Research

Metricath study to be presented at New Cardiovascular Horizons

RICHMOND, BRITISH COLUMBIA--(Marketwire - Sept. 5, 2007) - MEDICAL VENTURES CORP. (TSX VENTURE:MEV) announces that its Metricath Libra® arterial and in-stent measurement system will be featured in an emerging technology research presentation at the New Cardiovascular Horizons (NCVH) conference, taking place September 5-8 in New Orleans.

The conference will include the presentation of a study investigating the benefits of Metricath to measure stent expansion in the renal arteries. The study will be presented by Dr. Raed Aqel, interventional cardiologist at University of Alabama-Birmingham Hospital and Birmingham Veterans Affairs Medical Center.

"This is an opportunity for endovascular specialists from around the country to hear direct clinical feedback about the Metricath's performance as an arterial and in-stent measurement tool," said Kevin McKim, Medical Ventures' vice-president of sales and marketing. "Having a window into Dr. Aqel's experience and the Metricath's clinical applications related to renal artery procedures will be of tremendous benefit to doctors who have not yet had a chance to evaluate the technology."

The Metricath Libra is a balloon-tipped catheter used during angioplasty procedures to treat heart and vascular disease. The catheter features a low-pressure balloon that can precisely measure within arteries and stents, helping doctors with optimal stent selection and to confirm optimal stent expansion. The Metricath Libra is cleared for use in the United States, Canada, and the European Union.

Medical Ventures will exhibit the Metricath® System at several other industry tradeshows this fall, including:

- C3 - Capital Cardiovascular Conference - Harrisburg, PA, September 9-12

- VIVA - Vascular Interventional Advances - Las Vegas, NV, September 25-28

- TCT - Transcatheter Cardiovascular Therapeutics - Washington, DC, October 20-25

- VEITH Symposium - New York, NY, November 14-18

About NCVH

New Cardiovascular Horizons is the fourth largest cardiovascular conference in the United States. It has become the first and largest truly multidisciplinary conference to bring together over 3,000 cardiologists, fellows, residents, imaging professionals, cath lab techs, registered nurses, surgeons and many others to encompass the management, treatment and evaluation of all fields of medicine, with a primary focus on peripheral vascular disease and cardiovascular disease. Please visit

About Medical Ventures Corp.

Medical Ventures Corp. develops, manufactures and commercializes medical devices for the quickly growing vascular and surgical marketplace. MEV products help doctors treat a wide range of health concerns, including vascular disease and obesity. MEV products include the Metricath® vascular measurement system and PeriPatch™, a line of surgical tissue products. Medical Ventures is also a contract medical devices manufacturer. For more information, please visit

Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates", "believes", "may", "continues", "estimates", "expects", and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with Canadian securities regulators. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information